StockData
ELI LILLY & Co logo

ELI LILLY & Co (LLY) operating KPIs

LLYNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 20/3026% above fair value
$1417.54+43.84 (+3.19%)

Close on Oct 30, 2026Market cap $1.33TP/E 46.0Yield 0.44%

Eli Lilly verzenio (abemaciclib) — Worldwide revenue ($M) ($M)

Form 10-Q / 10-K Note 2, MD&A & Form 8-K Earnings Releases

QuarterlyAnnual
Latest, Q2 2026
1,474
Period ended Jun 30, 2026
Change on a year earlier
-1.0%
1,489 in Q2 2025
History
34 quarters
Since Q1 2018
Sources
30
Documents cited below

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedVerzenio (abemaciclib) — Worldwide revenue ($M) ($M)Year on yearSource
Q2 2026Jun 30, 20261,474-1.0%Form 10-Q (filed 2026-08-05) ↗
Q1 2026Mar 31, 20261,302+12.3%Form 10-Q (filed 2026-04-30) ↗
Q4 2025Dec 31, 20251,604+3.1%Earnings Release (Form 8-K FY2025Q4 EX-99.1) (filed 2026-02-04) ↗
Q3 2025Sep 30, 20251,470+7.4%Form 10-Q (filed 2025-10-30) ↗
Q2 2025Jun 30, 20251,489+11.8%Form 10-Q (filed 2026-08-05) ↗
Q1 2025Mar 31, 20251,159+10.3%Form 10-Q (filed 2026-04-30) ↗
Q4 2024Dec 31, 20241,555+35.8%Earnings Release (Form 8-K FY2024Q4 EX-99.1) (filed 2025-02-06) ↗
Q3 2024Sep 30, 20241,369+31.6%Form 10-Q (filed 2025-10-30) ↗
Q2 2024Jun 30, 20241,332+43.7%Form 10-Q (filed 2025-08-07) ↗
Q1 2024Mar 31, 20241,050+39.9%Form 10-Q (filed 2025-05-01) ↗
Q4 2023Dec 31, 20231,145+41.8%Earnings Release (Form 8-K FY2023Q4 EX-99.1) (filed 2024-02-06) ↗
Q3 2023Sep 30, 20231,040+68.4%Form 10-Q (filed 2024-10-30) ↗
Q2 2023Jun 30, 2023927+57.5%Form 10-Q (filed 2024-08-08) ↗
Q1 2023Mar 31, 2023751+60.0%Form 10-Q (filed 2024-04-30) ↗
Q4 2022Dec 31, 2022808+100.0%Earnings Release (Form 8-K FY2022Q4 EX-99.1) (filed 2023-02-02) ↗
Q3 2022Sep 30, 2022618+84.1%Form 10-Q (filed 2023-11-02) ↗

Breakdown

What makes up verzenio (abemaciclib) — worldwide revenue ($m)

Cite this data

StockData. (2026). Eli Lilly Verzenio (abemaciclib) — Worldwide revenue ($M) ($M), quarterly Q1 2018–Q2 2026 [Data set]. Compiled from Eli Lilly SEC filings and investor materials. https://stockdatahq.com/stocks/lly/kpis/med_verzenio_ww

See every metric in the Eli Lilly KPI table. Data updated Oct 25, 2026.